RICFY

PINK Recordati S.p.A. Unsponsored ADR
Oct 14, 2026 · 8:14 AM ET EOD Market Closed

$15.64 ↑ +0.56 (+3.70%) Trading Up from the previous close of $15.09, and at the day’s high of $15.64

YTD change
+18.78%
vs 20-day SMA
+7.06%
vs 200-day SMA
N/A

Price ranges

Previous day
$15.64 $15.64
open $15.64 close $15.64
+$0.00 (+0.00%)
Today
$15.64 $15.64
$15.64
Past week
$14.09 $15.22
from $14.84 now $15.64
+$0.80 (+5.42%)
Past month
$12.92 $15.75
from $15.39 now $15.64
+$0.25 (+1.65%)
This year
$9.29 $17.16
from $13.17 now $15.64
+$2.47 (+18.78%)

Price & Performance

+3.70 (+31.02%) / 6M

$10.18$12.26$14.35$16.43Apr 14Jul 20Oct 13

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Very Good
  • The stock is 8.8% away from all-time highs of $17.16
  • RICFY is up 19% since the beginning of the year
  • RICFY is up 19% over the past 12 months
  • RICFY is up 2% over the past 1 month

RICFY reads very good: the 12-month move is +6.1%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable Yes
EPS $0.1655
Earnings momentum N/A Quarterly EPS growth
Quarterly change N/A

Valuation

P/E ratio N/A
Enterprise value $13.7B
Beta 1.19

Balance sheet & scale

Income$581.2K
Revenue$3.2B
Cash$447.5M
Debt$2.6M
Income / Debt 0.22×

Company & Peers

Company profile and competitor comparison

Company profile

ExchangePINK
Market cap $12.8B

Recordati SpA engages in the research, development, manufacture, and marketing of pharmaceuticals. It operates through the Specialty and Primary Care, and Rare Diseases segments. The Specialty and Primary Care segment includes pharmaceutical chemical operations. The company was founded by Giovanni Recordati in 1926 and is headquartered in Milan, Italy.

Competitor comparison

No peer group available for this symbol.

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.